U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

Pfizer will stop developing an obesity pill that has been closely watched by investors, a severe blow in its efforts to ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A new guideline for treating obesity in children and adolescents says medication can be helpful, but that health providers ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

About half of Americans "strongly" or "somewhat" favor having Medicare and Medicaid cover weight-loss drugs for people who ...

GLP-1s like Ozempic, as well as weight-loss surgery, are among the recommendations to treat childhood obesity in the first guideline update in Canada in almost 20 years.